Exosome Diagnostics is Biotechnology in United States that focus on cell messengers business. Founded in 2008. They cover business area such as developer, biofluid-base diagnostic, personalize precision healthcare, life, exosome, important cell messenger, serum, plasma, urine, cerebrospinal fluid, saliva, RNA, DNA, protein, their cell, origin, health care organization, doctor, non-invasive diagnosis, serious disease, tissue biopsy.
2008
( 16 years old in 2024 )
Cell Messengers
-
266 Second Avenue
Suite 200
Waltham, MA 02451
United States
Private
developerbiofluid-base diagnosticpersonalize precision healthcarelifeexosomeimportant cell messengerserumplasmaurinecerebrospinal fluidsalivaRNADNAproteintheir celloriginhealth care organizationdoctornon-invasive diagnosisserious diseasetissue biopsy
* We use standard office opening hours in near Exosome Diagnostics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Exosome Diagnostics is Biotechnology business from United States that founded in 2008 (16 years old in 2024), Exosome Diagnostics business is focusing on Cell Messengers.
Exosome Diagnostics headquarter office and corporate office address is located in 266 Second Avenue Suite 200 Waltham, MA 02451 United States.
Exosome Diagnostics was founded in United States.
In 2024, Exosome Diagnostics is currently focus on cell messengers sector.
Above is snippet of Google Trends for "cell messengers" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Exosome Diagnostics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
